Elasmogen Receives £8 Million Investment
- Submitted by: Liam Kerr, North East Scotland, Scottish Conservative and Unionist Party.
- Date lodged: Thursday, 26 May 2022
- Motion reference: S6M-04588
That the Parliament congratulates Elasmogen for receiving an £8 million boost to help with what it sees as its pioneering research; notes that Elasmogen is a life science company based in Aberdeen, which, it understands, is currently developing drugs based on antibody-like molecules from sharks; understands that its soloMER binders are helping to create the next generation of biologics for inflammatory, autoimmune diseases and oncology, and reportedly have the potential to significantly improve the health of people in Scotland; applauds the work they are undertaking; understands that the biologics being developed are believed to be 10 times more effective than existing therapies for conditions including some cancers, rheumatoid arthritis and inflammatory bowel disease, and wishes all involved with what it sees as this ground-breaking work at Elasmogen all the best for the future.
Supported by:
Karen Adam, Jeremy Balfour, Colin Beattie, Miles Briggs, Alexander Burnett, Finlay Carson, Sharon Dowey, Russell Findlay, Murdo Fraser, Meghan Gallacher, Kenneth Gibson, Maurice Golden, Pam Gosal, Jamie Greene, Dr. Sandesh Gulhane, Craig Hoy, Stephen Kerr, Bill Kidd, Dean Lockhart, Douglas Lumsden, Fulton MacGregor, Stuart McMillan, Edward Mountain, Douglas Ross, Alexander Stewart, Paul Sweeney, Sue Webber, Tess White, Brian Whittle